Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Maxim Group Downgrades BioLineRx (BLRX) to HoldAugust 12, 2016 6:29 AM BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 MilestonesAugust 11, 2016 7:19 AM Form 6-K BioLineRx Ltd. For: Aug 11August 11, 2016 7:15 AM BioLineRx Reports Second Quarter 2016 Financial ResultsAugust 11, 2016 7:15 AM BioLineRx (BLRX) Appoints New CEOAugust 11, 2016 6:47 AM Form 6-K BioLineRx Ltd. For: Aug 11August 11, 2016 6:45 AM BioLineRx Names Philip A. Serlin as Chief Executive OfficerAugust 11, 2016 6:45 AM